Clinical trial · Interventional
Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will investigate health related quality of life factors in patients undergoing low dose rate prostate brachytherapy. Patients will be randomized to Iodine-125 Thinstrand (for use with 20 g needles) or Rapidstrand (for use with standard 18 g needles). Urinary, bowel, sexual function and bother will be measured by the EPIC questionnaire at various time intervals.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RapidStrand seeds for use with 18g needle | Device | — | UNRESOLVED |
| ThinStrand | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Iodine-125 standard 18 g needle
- description
- Rapidstrand
- interventionNames
- Device: RapidStrand seeds for use with 18g needle
- Device: ThinStrand
- type
- ACTIVE_COMPARATOR
- label
- 20 g needle
- description
- Thin Strand
- interventionNames
- Device: RapidStrand seeds for use with 18g needle
- Device: ThinStrand
Primary outcomes (1)
- measure
- Health related quality of life including urinary, bowel and sexual function as measured by the EPIC questionnaire
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate, clinical stage T1c - T2b, N0, M0 * Greater than or equal to 40 years of age * Low and Low- Intermediate Risk prostate cancer * Prostate volumes by TRUS ≤ 60 cc * I-PSS score \< 25 (alpha blockers allowed) * Signed study-specific informed consent form prior to study entry Exclusion Criteria: * Lymph node involvement (N1) * Evidence of distant metastases (M1) * Radical surgery for carcinoma of the prostate * Prior pelvic radiation * Major medical or psychiatric illness, which in the investigator's opinion would prevent completion of treatment and would interfere with follow- up or ability to complete questionnaires * Hip prosthesis * Inability or refusal to provide informed consent * Evidence of Previous TURP * Prior hormone therapy * Prior TURP
References
Publications (0)
Data not yet available